Literature DB >> 24323993

Residual scarring from hidradenitis suppurativa: fractionated CO2 laser as a novel and noninvasive approach.

Andrew C Krakowski1, Shehla Admani, Nathan S Uebelhoer, Lawrence F Eichenfield, Peter R Shumaker.   

Abstract

Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin condition that can have a significant psychosocial impact, both with the active disease and with residual scarring. Although a wide variety of treatment options exist for HS, to our knowledge there are no reported modalities aimed specifically at treating HS scarring. We describe the case of an adolescent female who received medical management of intramammary HS followed by successful treatment with fractionated 10,600-nm carbon dioxide laser for her residual cribriform scarring. We believe there is great potential for the use of fractionated carbon dioxide laser to improve short- and long-term psychosocial outcomes of HS, promote physical scar remodeling, and possibly alter the disease process itself.

Entities:  

Keywords:  carbon dioxide; fractionated; hidradenitis suppurativa; photothermolysis; scarring

Mesh:

Year:  2013        PMID: 24323993     DOI: 10.1542/peds.2012-3356

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  3 in total

Review 1.  Hidradenitis suppurativa in children and adolescents: a review of treatment options.

Authors:  Peter Riis Mikkelsen; Gregor B E Jemec
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

2.  Disfiguring Hidradenitis Suppurativa of the Face.

Authors:  Gianmarco Capasso; Gabriella Fabbrocini; Claudio Marasca
Journal:  Skin Appendage Disord       Date:  2021-08-26

3.  Rapid healing of chronic ulcerations and improvement in range of motion after fractional carbon dioxide (CO2) treatment after CO2 excision of hidradenitis suppurativa axillary lesions: A case report.

Authors:  Cynthia L Nicholson; Iltefat Hamzavi; David M Ozog
Journal:  JAAD Case Rep       Date:  2016-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.